MedTrace Logo

Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

NCT05253833 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2025-01-29

No results posted yet for this study

Summary

This study will assess the serum urate lowering effect, tophi reduction, and safety of AR882 alone and in combination with allopurinol in patients with tophaceous gout at two doses compared to allopurinol over 24 weeks.

Conditions

  • Gout
  • Arthritis, Gouty
  • Hyperuricemia
  • Gout Chronic

Interventions

DRUG

AR882 Dose 1

Solid Oral Capsule

DRUG

AR882 Dose 2

Solid Oral Capsule

DRUG

Allopurinol Tablet

Solid tablet

Sponsors & Collaborators

  • Arthrosi Therapeutics

    lead INDUSTRY

Principal Investigators

  • R Keenan, MD · Arthrosi Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-12
Primary Completion
2024-08-13
Completion
2024-10-28
FDA Drug
Yes

Countries

  • United States
  • New Zealand
  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05253833 on ClinicalTrials.gov